“OUTCOMES OF SUBSEQUENT TREATMENT AFTER ATEZOLIZUMAB–BEVACIZUMAB FOR HEPATOCELLULAR CARCINOMA”, YHCĐ, vol. 67, no. 10, Oct. 2026, doi: 10.52163/yhc.v67i10.6872.